5513 Background: The goal of this study was to investigate the safety and efficacy of
cetuximab (Erbitux), an IgG1 monoclonal antibody targeting the EGFR, given in combination …

Purpose This was an open, randomized, multicenter, phase I/II study to investigate the safety
and tolerability of cetuximab in the first-line treatment of recurrent/metastatic squamous cell …

5502 Background: Pts with refractory SCCHN have a poor prognosis with few therapeutic
options. Cetuximab (Erbitux), an IgG1 monoclonal antibody that binds selectively to EGFR …

5537 Background: The epidermal growth factor receptor (EGFR) is expressed in nearly all
SCCHN and carries a strong prognostic significance, providing the rationale for using EGFR …

5505 Background: Patients with R&M SCCHN have a poor prognosis. Patients failing first-
line therapy have few therapeutic options. Cetuximab (Erbitux) is an IgG1 monoclonal …

BACKGROUND. The epidermal growth factor receptor (EGFR) inhibitor cetuximab is active
in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The …

6001 Objective: Phase I study to determine the maximum tolerated dose (MTD) of 5-FU in
the Docetaxel/Cisplatin/5-Fluorouracil (TPF) regimen (Posner et al, NEJM 2007) when …

Simple Summary The purpose of the CET-MET trial was to find a new platinum-based
chemotherapy regimen in combination with cetuximab for relapsed or metastatic squamous …

Abstract Learning Objectives Compare survival outcomes among patients with SCCHN
treated with a platinum/5‐FU regimen with and without cetuximab. Compare adverse event …

6032 Background: Platinum-based chemotherapy with cetuximab is the standard of care for
relapsed or metastatic squamous cell carcinoma of the head and neck (SCCHN). The aim of …